BACKGROUND: The alleles of the Wilms tumor 1 (WT1) polymorphism rs16754 harbor adenine (A) or guanine (G). Recently, rs16754 has been reported to affect the outcome of patients with cytogenetically normal acute myeloid leukemia. To validate this finding, we investigated pretreatment features and outcome associated with rs16754 in a large cohort of patients with cytogenetically normal acute myeloid leukemia. DESIGN AND METHODS: Four-hundred and thirty-three intensively treated and molecularly characterized cytogenetically normal patients with de novo acute myeloid leukemia (18-83 years old) were analyzed for rs16754. To gain biological insights, we studied the gene- and microRNA-expression profiles for associations with rs16754. RESULTS: Three-hundred and nine (71%) patients were homozygous for A (WT1(AA)), 112 (26%) were heterozygous (WT1(AG)) and 12 (3%) were homozygous for G (WT1(GG)). For comparison with previous studies, we grouped WT1(AG) and WT1(GG) patients and compared them with WT1(AA) patients divided into younger (<60 years) and older (≥60 years) adults. We found no independent prognostic impact of WT1(AA). However, WT1(GG) patients, who were less often Caucasian than WT1(AG) (P=0.001) or WT1(AA) (P=0.008) patients, and had TET2 mutations more often than WT1(AG) (P=0.02) patients, had, among patients with FLT3-internal tandem duplication and/or NPM1 wild-type, better disease-free (P=0.02) and overall survival (P=0.04) than WT1(AA) and WT1(AG) patients combined. Unsupervised and supervised analyses of the gene- and microRNA-expression profiles suggested that there were no distinct expression patterns associated with any rs16754 genotype. CONCLUSIONS: We did not observe the previously reported adverse impact of WT1(AA) but found favorable outcomes associated with the homozygous WT1(GG). Considering its low frequency, confirmatory studies are necessary. The biological significance of rs16754 remains questionable as no distinct expression profiles were associated with the genotypes.
BACKGROUND: The alleles of the Wilms tumor 1 (WT1) polymorphism rs16754 harbor adenine (A) or guanine (G). Recently, rs16754 has been reported to affect the outcome of patients with cytogenetically normal acute myeloid leukemia. To validate this finding, we investigated pretreatment features and outcome associated with rs16754 in a large cohort of patients with cytogenetically normal acute myeloid leukemia. DESIGN AND METHODS: Four-hundred and thirty-three intensively treated and molecularly characterized cytogenetically normal patients with de novo acute myeloid leukemia (18-83 years old) were analyzed for rs16754. To gain biological insights, we studied the gene- and microRNA-expression profiles for associations with rs16754. RESULTS: Three-hundred and nine (71%) patients were homozygous for A (WT1(AA)), 112 (26%) were heterozygous (WT1(AG)) and 12 (3%) were homozygous for G (WT1(GG)). For comparison with previous studies, we grouped WT1(AG) and WT1(GG) patients and compared them with WT1(AA) patients divided into younger (<60 years) and older (≥60 years) adults. We found no independent prognostic impact of WT1(AA). However, WT1(GG) patients, who were less often Caucasian than WT1(AG) (P=0.001) or WT1(AA) (P=0.008) patients, and had TET2 mutations more often than WT1(AG) (P=0.02) patients, had, among patients with FLT3-internal tandem duplication and/or NPM1 wild-type, better disease-free (P=0.02) and overall survival (P=0.04) than WT1(AA) and WT1(AG) patients combined. Unsupervised and supervised analyses of the gene- and microRNA-expression profiles suggested that there were no distinct expression patterns associated with any rs16754 genotype. CONCLUSIONS: We did not observe the previously reported adverse impact of WT1(AA) but found favorable outcomes associated with the homozygous WT1(GG). Considering its low frequency, confirmatory studies are necessary. The biological significance of rs16754 remains questionable as no distinct expression profiles were associated with the genotypes.
Authors: Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Martin Zimmermann; Brian V Balgobind; Susan T C J M Arentsen-Peters; Marielle Alders; Andre Willasch; Gert-Jan J L Kaspers; Jan Trka; Andre Baruchel; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; C Michel Zwaan Journal: J Clin Oncol Date: 2010-07-19 Impact factor: 44.544
Authors: Phoenix A Ho; Julia Kuhn; Robert B Gerbing; Jessica A Pollard; Rong Zeng; Kristen L Miller; Nyla A Heerema; Susana C Raimondi; Betsy A Hirsch; Janet L Franklin; Beverly Lange; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: Heiko Becker; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Susan P Whitman; Peter Paschka; Kelsi B Holland; Sebastian Schwind; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield Journal: Blood Date: 2010-05-04 Impact factor: 22.113
Authors: Klaus H Metzeler; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Heiko Becker; John Curfman; Kelsi B Holland; Sebastian Schwind; Susan P Whitman; Yue-Zhong Wu; William Blum; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Heiko Becker; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Peter Paschka; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2009-12-21 Impact factor: 44.544
Authors: Susan P Whitman; Kati Maharry; Michael D Radmacher; Heiko Becker; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Yue-Zhong Wu; Sebastian Schwind; Klaus H Metzeler; Jing Wen; Maria R Baer; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Joseph O Moore; Richard M Stone; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield Journal: Blood Date: 2010-07-23 Impact factor: 22.113
Authors: Margaret M Byrne; L Jill Halman; Leonidas G Koniaris; Peter A Cassileth; Joseph D Rosenblatt; Michael C Cheung Journal: Am J Clin Oncol Date: 2011-06 Impact factor: 2.339
Authors: Sebastian Schwind; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Heiko Becker; Susan P Whitman; Yue-Zhong Wu; Klaus H Metzeler; Bayard L Powell; Jonathan E Kolitz; Thomas H Carter; Joseph O Moore; Maria R Baer; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield Journal: Blood Date: 2010-09-14 Impact factor: 22.113
Authors: Frederik Damm; Michael Heuser; Michael Morgan; Haiyang Yun; Anika Grosshennig; Gudrun Göhring; Brigitte Schlegelberger; Konstanze Döhner; Oliver Ottmann; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna Raghavachar; Walter Fiedler; Hartmut Kirchner; Hartmut Döhner; Gerhard Heil; Arnold Ganser; Jürgen Krauter Journal: J Clin Oncol Date: 2009-12-28 Impact factor: 44.544
Authors: Xiao-Wei Qi; Xiao-Dong Zheng; Bei-Ge Zong; Qing-Qiu Chen; Fan Zhang; Xin-Hua Yang; Yi Zhang; Jun-Lan Liu; Jun Jiang Journal: Am J Cancer Res Date: 2015-02-15 Impact factor: 6.166
Authors: J E Megías-Vericat; M J Herrero; L Rojas; P Montesinos; V Bosó; F Moscardó; D Martínez-Cuadrón; J L Poveda; M Á Sanz; S F Aliño Journal: Pharmacogenomics J Date: 2015-12-08 Impact factor: 3.550